Table1:

Patient Demographics

ID	AAO	AAD	Sex	Clinical Diagnosis	Path Diagnosis	Braak	Thal	CERAD	ABC	Mutation
sAD1	43	58	F	AD	AD	VI	5	2	A3B3C2
sAD2	54	65	M	AD	AD	VI	5	3	A3B3C3
sAD3	58	68	M	PCA	AD	VI	5	3	A3B3C3
sAD4	55	67	F	PPA	AD	VI	5	3	A3B3C3
sAD5	63	79	M	AD	AD	VI	5	3	A3B3C3
sAD6	49	69	F	AD	AD	VI	5	2	A3B3C2
sAD7	48	63	M	AD	AD	VI	5	3	A3B3C3
sAD8	51	62	F	AD	AD	VI	5	3	A3B3C3
sAD9	50	66	F	PPA	AD	vi	5	3	A3B3C4
fAD1	42	47	M	FAD	FAD	V	5	3	A3B3C3	PSEN1 A434T & T291A
fAD2	46	65	F	FAD	FAD	VI	5	3	A3B3C3	PSEN1 after 200 (R278I)
fAD3	35	51,9	F	FAD	FAD	VI	5	3	A3B3C3	PSEN1 Intron 4
fAD4	33	37	F	FAD	FAD	VI	5	3	A3B3C3	PSEN1 E120K
fAD5	47	58	F	FAD	FAD	VI	5	3	A3B3C3	PSEN1 E184D
fAD6	42	51	M	FAD	FAD	VI	5	3	A3B3C3	PSEN1 mutation (Intron 4)

AAO: age at onset; AAD: age at death; PCA: posterior cortical atrophy; PPA: primary progressive aphasia; PSEN1: Presenilin 1; CERAD: Consortium to Establish a Registry for Alzheimer’s Disease; ABC, Combined score based on Thal phase, Braak stage and CERAD Score